# Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
Canonical URL: https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-publication-in-new-england-journal-of-medicine-of-phase-1-2-clinical-data-on-daraxonrasib-in-pancreatic-cancer
Ticker: RVMD
Company: Revolution Medicines
Source: Revolution Medicines
Published: 2026-05-06 22:00 EST
Original Source URL: https://ir.revmed.com
## Summary

Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer REDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing

## Article Body
Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer REDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing
## Recent Company News
- 2026-05-31 12:06 EST — [Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer](https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-asco-plenary-presentation-highlighting-unprecedented-results-from-pivotal-phase-3-rasolute-302-clinical-trial-of-daraxonrasib-in-previously-treated-metastatic-pancreatic-cancer) — Source: Revolution Medicines
- 2026-05-21 20:05 EST — [Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation](https://biopharmsignal.com/news/RVMD/revolution-medicines-to-host-investor-conference-call-on-positive-rasolute-302-results-following-2026-asco-presentation) — Source: Revolution Medicines
- 2026-05-06 22:00 EST — [Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer](https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-publication-in-new-england-journal-of-medicine-of-phase-1-2-clinical-data-on-daraxonrasib-in-pancreatic-cancer) — Source: Revolution Medicines
- 2026-05-06 20:02 EST — [Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress](https://biopharmsignal.com/news/RVMD/revolution-medicines-reports-first-quarter-2026-financial-results-and-update-on-corporate-progress) — Source: Revolution Medicines
- 2026-05-01 14:41 EST — [Revolution Medicines Statement on FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer](https://biopharmsignal.com/news/RVMD/revolution-medicines-statement-on-fda-expanded-access-authorization-for-daraxonrasib-in-patients-with-previously-treated-metastatic-pancreatic-cancer) — Source: Revolution Medicines
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)